Practice guideline outlines rational pharmacotherapy schemes for COVID-19 in clinical healthcare, highlighting the need to curb unjustified antimicrobial treatments.
The treatment of patients with a new coronavirus infection (COVID-19) is the cornerstone of practical healthcare. This is due to the widespread and unjustified use of antimicrobial drugs, the use of irrational antiviral therapy schemes. Also, the discussion regarding the use of systemic glucocorticosteroids and monoclonal antibodies continues to this day. In this publication, based on research data and own clinical observations, clinical recommendations for COVID-19 pharmacotherapy are presented.
No takes yet. Share an insight, caveat, or question.
А. А. Зайцев (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: